The nature of the compensatory response to low thyroid hormone in the developing brain.
Thyroid hormone is essential for normal brain development, although the degree to which the developing brain is sensitive to small perturbations in serum thyroxin is not clear. An important concept related to this is that the developing brain possesses potent mechanisms to compensate for low serum thyroid hormone, and this concept is routinely employed in discussions concerning clinical treatments or public health. However, experimental studies have not directly tested whether (or the degree to which) putative compensatory mechanisms can ameliorate the consequences of small reductions in serum thyroxin (T(4)). To formally test this concept, we employed a model of graded T(4) reductions using doses of propylthiouracil (PTU) that were 200- to 67-fold lower than the dose traditionally used to produce hypothyroidism in rats. PTU produced a stepwise decrease in serum total T(4), and a stepwise increase in serum thyroid-stimulating hormone (TSH), in type 2 deiodinase mRNA expression and enzyme activity in the brain, and in the expression of the mRNA encoding the tri-iodothyronine (T(3)) transporter MCT8 in the postnatal day (P) 15 cortex. However, the mRNA encoding RC3/neurogranin, a direct target of T(3) action, exhibited a strong negative linear correlation with serum total T(4) despite these adaptive responses. In addition, single-cell analysis of RC3 mRNA levels in cortical neurones demonstrated that the co-expression of MCT8 did not alter the relationship between RC3 mRNA and serum T(4). These findings do not support the currently envisioned concept of the developing brain being capable of compensating for low T(4).
Sharlin
D S
DS
Molecular and Cellular Biology Program, University of Massachusetts, Amherst, MA 01003, USA.
Gilbert
M E
ME
Taylor
M A
MA
Ferguson
D C
DC
Zoeller
R T
RT
D000818:Animals; D013956:Antithyroid Agents / Q000494:pharmacology; D001921:Brain / Q000201:enzymology / Q000254:growth & development*; D005260:Female; D007037:Hypothyroidism / Q000378:metabolism*; D007453:Iodide Peroxidase / Q000378:metabolism; D008297:Male; D008713:Methimazole / Q000494:pharmacology; D027501:Monocarboxylic Acid Transporters / Q000378:metabolism; D051579:Neurogranin / Q000378:metabolism; D010472:Perchlorates / Q000494:pharmacology; D011441:Propylthiouracil / Q000494:pharmacology; D051381:Rats; D020318:Rats, Long-Evans; D017207:Rats, Sprague-Dawley; D013972:Thyrotropin / Q000097:blood*; D013974:Thyroxine / Q000037:antagonists & inhibitors / Q000097:blood / Q000502:physiology*
D013956:Antithyroid Agents; D027501:Monocarboxylic Acid Transporters; C496651:Nrgn protein, rat; D010472:Perchlorates; C478998:monocarboxylate transporter 8, rat; D051579:Neurogranin; D008713:Methimazole; D011441:Propylthiouracil; D013972:Thyrotropin; D007453:Iodide Peroxidase; D013974:Thyroxine; C494474:perchlorate